April 28, 2022 06:15 AM EDTUpdated 08:50 AM

Eli Lilly throws down the gauntlet in obesity race, challenging Novo Nordisk with new PhIII readout

Max Gelman

Senior Editor

Amber Tong

Senior Editor

Novo Nordisk made waves early last year after showing that its blockbuster diabetes drug was also highly effective at treating non-diabetic adults with obesity. But …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eli Lilly throws down the gauntlet in obesity race, challenging Novo Nordisk with new PhIII readout

Max Gelman

Senior Editor

Amber Tong

Senior Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Eli Lil­ly throws down the gaunt­let in obe­si­ty race, chal­leng­ing No­vo Nordisk with new PhI­II read­out

Senior Editor

Senior Editor

Sign up to read this article for free.

Eli Lilly throws down the gauntlet in obesity race, challenging Novo Nordisk with new PhIII readout